Ascendis Pharma A/S

FRC's fair value estimate for Ascendis Pharma A/S, and the rating behind it. ASND last traded at $263.51, 18.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Ascendis Pharma A/S. Starting points for Ascendis Pharma A/S: P/E 18.8, EPS $11.75, beta 0.38 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Ascendis Pharma A/S. Ascendis Pharma A/S does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Ascendis Pharma A/S. Trailing twelve-month EPS for Ascendis Pharma A/S stands at $11.75. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Ascendis Pharma A/S. Ascendis Pharma A/S has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Ascendis Pharma A/S valued side by side against its closest peers. Ascendis Pharma A/S is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Ascendis Pharma A/S, and how their positions are changing. At a $16.37B market value, institutional positions materially move Ascendis Pharma A/S's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Ascendis Pharma A/S executives and directors. Shares of Ascendis Pharma A/S have traded between $118.03 and $223.19 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Ascendis Pharma A/S. Ascendis Pharma A/S is a $16.37B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Ascendis Pharma A/S. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Ascendis Pharma A/S. Coverage tracks Ascendis Pharma A/S within Biotechnology (Healthcare). Press releases and market coverage, newest first.